Growth hormone secretagogues derived from NN703 with hydrazidesas c-terminal.
A series of GH secretagogues based on modifications in the C-terminal of NN703 is reported. The C-terminal N-methyl amide of NN703 has been replaced with alkylated hydrazides in order to decrease the volume of distribution and identify GH secretagogues with shorter duration of action. Most of the prepared compounds show high potency in a rat pituitary assay. Subsequent to an initial in vivo screening in dogs, four compounds were selected for further pharmacological and pharmacokinetic evaluation. The four compounds showed oral bioavailability around 35% and equipotency in vitro compared to NN703. The relationship between lipophilicity and volume of distribution is discussed and it is speculated whether the lower volume of distribution is attributed to the observed higher in vivo potency and shorter plasma elimination half-life.
Ankersen
M
M
Health Care Chemistry, Novo Nordisk A/S, Novo Nordisk Park, DK-2760, Mâløv, Denmark. miak@novo.dk
Kramer Nielsen
K
K
Kruse Hansen
T
T
Raun
K
K
Sehested Hansen
B
B
D000818:Animals; D004151:Dipeptides / Q000737:chemistry / Q000494:pharmacology; D004285:Dogs; D013006:Growth Hormone / Q000378:metabolism; D013007:Growth Hormone-Releasing Hormone / Q000031:analogs & derivatives*; D006728:Hormones / Q000138:chemical synthesis*; D006834:Hydrazines / Q000138:chemical synthesis* / Q000494:pharmacology; D015394:Molecular Structure; D009842:Oligopeptides / Q000138:chemical synthesis*; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism; D051381:Rats
D004151:Dipeptides; D006728:Hormones; D006834:Hydrazines; D009842:Oligopeptides; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone; C120631:tabimorelin